🔗 Share this article

As America undertakes historic adjustments to its vaccine recommendations, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by casting doubt on coronavirus shots throughout the pandemic and has focused upon alleged deaths after Covid immunization in her short position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Schedule

Public health authorities had intended to announce sweeping changes to the childhood vaccination calendar recently, aligning the US with Denmark’s immunization schedule, sources say – a major change that would put the US at odds with many the global community with little proof for improved outcomes. The planned update has been delayed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

A Shift at the FDA

The acting appointment might represent a closer partnership between the drug and biologics divisions as Høeg and Prasad solidify control at the FDA – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing some childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a country with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – usually the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Background

The appointee has no apparent background in medication creation, approval processes or administrative roles, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in managing a large organization. She lacks background in industry regulation.”

Past directors of the center would “understand laws and regulations and the science of medication creation”, noted a former acting FDA commissioner. “Frankly, she lacks the kind of background that former directors who headed the center have had.”

CDER has an enormous portfolio at the FDA, Woodcock pointed out.

“The public just pays attention on the new drug program, but the generic drug division approves thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these must be managed,” Dr. Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major administrative component to the position, which supervises more than 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” Woodcock said.

Response and Contentious Initiatives

When asked about inquiries about Høeg’s qualifications and whether this selection signifies increased cooperation among FDA leaders on vaccines, a press secretary said that the “inquiries rely on inaccurate assumptions”.

“Her experience is consistent with the duties of her role,” the spokesperson said, citing the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's new priority voucher program, a disputed expedited drug-approval program that apparently concerned her preceding directors. “How are these medications being picked for this fast-track system? Who makes the choices?” Howard questioned. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he remarked, “the agency looks to be trending towards more relaxed regulations of all drugs, with the exception of shots.”

Public History on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if troubling, history, Howard observe. She authored a analysis using unconfirmed volunteer-provided data to assess the frequency of myocarditis after COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership encompassed altering regulations for new vaccines and ending “non-essential” vaccines, she said following the vote on a online show. At the agency, Høeg has according to sources proposed excluding teenage boys from getting Covid vaccines.

“She’s an thorough ideologue who starts off with her conclusions and tailors the evidence to retrofit the data in a extremely misleading, fraudulent way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|